Market Expansion: Dapagliflozin Receives FDA Approval for Treating Type 2 Diabetes in Children 2024-06-13
AstraZeneca has announced on June 12, 2024, that Farxiga (dapagliflozin) has been approved by the U.S. Food and Drug Administration (FDA) for improving glycemic control in children aged 10 years and above with type 2 diabetes (T2D). The FDA approval is based on the positive results from the Phase 3
Read More